https://www.nasdaq.com/press-release/beigene-expands-collaboration-with-novartis-to-develop-and-commercialize-beigenes
https://www.nasdaq.com/press-release/beigene-announces-launch-of-bioisland-innovation-center-2021-12-20
https://www.nasdaq.com/press-release/beigene-announces-authorisation-of-brukinsa-zanubrutinib-from-the-united-kingdoms
https://www.nasdaq.com/press-release/beigene-announces-closing-of-its-rmb22.2-billion-us%243.5-billion-initial-public
https://www.nasdaq.com/press-release/nanjing-leads-biolabs-and-beigene-announce-worldwide-license-and-collaboration
https://www.nasdaq.com/press-release/beigene-presents-results-from-sequoia-trial-of-brukinsa-zanubrutinib-in-first-line
https://www.nasdaq.com/press-release/beigene-presents-updated-safety-and-efficacy-findings-on-brukinsa-zanubrutinib-in-btk
https://www.nasdaq.com/press-release/beigene-presents-results-from-phase-3-trial-of-tislelizumab-in-nasopharyngeal-cancer
https://www.nasdaq.com/press-release/direxion-launches-mrna-etf-msgr-2021-12-09
https://www.nasdaq.com/press-release/beigene-and-eusa-pharma-announce-nmpa-approval-of-sylvantr-siltuximab-for-injection
https://www.nasdaq.com/press-release/beigene-and-eusa-pharma-announce-nmpa-approval-of-sylvantr-siltuximab-for-injection-0
https://www.nasdaq.com/press-release/beigene-announces-inclusion-in-the-china-national-reimbursement-drug-list-nrdl-of
https://www.nasdaq.com/press-release/beigene-to-present-new-clinical-data-on-tislelizumab-at-esmo-io-congress-2021-2021-12
https://www.nasdaq.com/press-release/beigene-announces-pricing-of-its-rmb22.2-billion-us%243.5-billion-initial-public
https://www.nasdaq.com/press-release/beigene-announces-approval-of-brukinsa-zanubrutinib-in-the-european-union-for
https://www.nasdaq.com/press-release/beigene-launches-proposed-initial-public-offering-on-the-star-market-in-china-2021-11
https://www.nasdaq.com/press-release/beigene-closes-on-property-for-new-u.s.-manufacturing-and-clinical-rd-center-2021-11
https://www.nasdaq.com/press-release/beigene-initiates-first-in-human-phase-1-clinical-trial-of-investigational-tyk2
https://www.nasdaq.com/press-release/beigene-and-newbridge-pharmaceuticals-announce-approval-in-saudi-arabia-of-brukinsar
https://www.nasdaq.com/press-release/beigene-reports-third-quarter-2021-financial-results-2021-11-04
https://www.nasdaq.com/press-release/beigene-to-present-clinical-data-on-brukinsa-in-chronic-lymphocytic-leukemia-at-the
https://www.nasdaq.com/press-release/beigene-and-nanolek-announce-approval-in-russia-for-brukinsar-zanubrutinib-for
https://www.nasdaq.com/press-release/beigene-announces-brukinsar-zanubrutinib-approved-for-treatment-of-patients-with
https://www.nasdaq.com/press-release/beigene-announces-first-regulatory-approval-in-australia-for-brukinsar-zanubrutinib
https://www.nasdaq.com/press-release/beigene-announces-inclusion-in-ftse-russell-indices-2021-09-20
https://www.nasdaq.com/press-release/beigene-receives-positive-chmp-opinion-for-brukinsar-zanubrutinib-for-the-treatment
https://www.nasdaq.com/press-release/u.s.-fda-grants-brukinsar-zanubrutinib-accelerated-approval-in-relapsed-or-refractory
https://www.nasdaq.com/press-release/beigene-announces-u.s.-fda-acceptance-of-biologics-license-application-for
https://www.nasdaq.com/press-release/beigene-to-present-latest-findings-in-robust-lung-cancer-portfolio-at-esmo-congress
https://www.nasdaq.com/press-release/u.s.-fda-grants-brukinsar-zanubrutinib-approval-in-waldenstroms-macroglobulinemia
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-2
https://www.nasdaq.com/press-release/beigene-announces-acceptance-by-swissmedic-of-marketing-authorization-application-for
https://www.nasdaq.com/press-release/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarzibar-dinutuximab-beta-0
https://www.nasdaq.com/press-release/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarzibar-dinutuximab-beta-for
https://www.nasdaq.com/press-release/beigene-to-host-investor-conference-call-and-webcast-to-discuss-the-companys-early-0
https://www.nasdaq.com/press-release/beigene-reports-second-quarter-2021-financial-results-2021-08-05
https://www.nasdaq.com/press-release/beigene-announces-plans-to-build-new-manufacturing-and-clinical-rd-center-at
https://www.nasdaq.com/press-release/beigene-announces-positive-topline-results-from-phase-3-sequoia-trial-comparing
https://www.nasdaq.com/press-release/beigene-announces-approval-in-canada-of-brukinsar-zanubrutinib-for-the-treatment-of
https://www.nasdaq.com/press-release/beigene-announces-the-approval-in-china-of-kyprolisr-carfilzomib-for-injection-for
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-1
https://www.nasdaq.com/press-release/puretech-announces-clinical-trial-and-supply-agreement-with-beigene-to-evaluate-lyt
https://www.nasdaq.com/press-release/china-nmpa-approves-tislelizumab-in-non-small-cell-lung-cancer-and-hepatocellular
https://www.nasdaq.com/press-release/beigene-announces-china-nmpa-approval-of-brukinsar-zanubrutinib-for-the-treatment-of
https://www.nasdaq.com/press-release/beigene-announces-first-patient-dosed-in-global-phase-3-trial-of-anti-tigit-antibody
https://www.nasdaq.com/press-release/beigene-presents-long-term-efficacy-and-safety-results-from-three-pivotal-trials-of
https://www.nasdaq.com/press-release/beigene-presents-alpine-results-at-eha2021-demonstrating-both-efficacy-and-safety
https://www.nasdaq.com/press-release/shoreline-biosciences-and-beigene-announce-strategic-worldwide-collaboration-to
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-0
https://www.nasdaq.com/press-release/beigene-presents-clinical-data-from-two-phase-2-trials-of-pamiparib-at-the-2021-asco
https://www.nasdaq.com/press-release/beigene-presents-clinical-data-from-two-pivotal-trials-of-tislelizumab-at-the-2021
https://www.nasdaq.com/press-release/zhongchao-inc.-announces-the-on-going-one-year-leukemia-education-project-with
https://www.nasdaq.com/press-release/beigene-announces-first-presentation-of-the-phase-3-alpine-trial-comparing-brukinsar
https://www.nasdaq.com/press-release/beigene-announces-positive-topline-results-from-phase-3-trial-of-tislelizumab-in
https://www.nasdaq.com/press-release/beigene-to-showcase-broad-clinical-portfolio-at-2021-asco-annual-meeting-2021-05-19
https://www.nasdaq.com/press-release/beigene-announces-u.s.-fda-acceptance-and-priority-review-of-supplemental-new-drug
https://www.nasdaq.com/press-release/beigene-highlights-progress-in-hematology-at-eha2021-virtual-congress-2021-05-13
https://www.nasdaq.com/press-release/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated
https://www.nasdaq.com/press-release/beigene-reports-first-quarter-2021-financial-results-2021-05-06
https://www.nasdaq.com/press-release/brukinsar-zanubrutinib-demonstrates-superior-objective-response-rate-by-investigator
https://www.nasdaq.com/press-release/beigene-presents-interim-analysis-results-of-rationale-303-trial-of-tislelizumab-in
https://www.nasdaq.com/press-release/beigene-presents-clinical-data-on-sitravatinib-in-combination-with-tislelizumab-at
https://www.nasdaq.com/press-release/beigene-provides-update-on-phase-2-clinical-trial-of-zanubrutinib-in-patients-with
https://www.nasdaq.com/press-release/beigene-launches-brukinsar-zanubrutinib-in-canada-for-patients-with-waldenstroms
https://www.nasdaq.com/press-release/beigene-announces-first-commercial-manufacturing-approval-for-its-state-of-the-art
https://www.nasdaq.com/press-release/beigene-announces-new-chief-financial-officer-julia-wang-2021-03-30
https://www.nasdaq.com/press-release/111-inc.-enters-into-first-ever-strategic-partnership-with-beigene-2021-03-17
https://www.nasdaq.com/press-release/beigene-announces-presentation-of-clinical-and-preclinical-data-at-the-aacr-annual
https://www.nasdaq.com/press-release/beigene-initiates-phase-1-clinical-trial-for-hpk1-inhibitor-bgb-15025-2021-03-10
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china
https://www.nasdaq.com/press-release/health-canada-approves-brukinsar-zanubrutinib-for-the-treatment-of-waldenstroms
https://www.nasdaq.com/press-release/beigene-announces-closing-of-collaboration-with-novartis-to-develop-and-commercialize
https://www.nasdaq.com/press-release/beigene-reports-fourth-quarter-and-full-year-2020-financial-results-2021-02-25
https://www.nasdaq.com/press-release/boston-immune-technologies-and-therapeutics-and-beigene-enter-into-an-exclusive
https://www.nasdaq.com/press-release/beigene-announces-u.s.-fda-acceptance-of-supplemental-new-drug-application-for
https://www.nasdaq.com/press-release/beigene-announces-positive-topline-results-for-global-phase-3-trial-of-tislelizumab
https://www.nasdaq.com/press-release/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for-0
https://www.nasdaq.com/press-release/china-national-medical-products-administration-approves-tislelizumab-in-combination
https://www.nasdaq.com/press-release/beigene-announces-collaboration-with-novartis-to-develop-and-commercialize-anti-pd-1
https://www.nasdaq.com/press-release/strand-therapeutics-and-beigene-enter-into-agreement-to-develop-solid-tumor-immuno
https://www.nasdaq.com/press-release/beigene-to-present-at-the-j.p.-morgan-39th-annual-healthcare-conference-2021-01-07
https://www.nasdaq.com/press-release/beigene-announces-inclusion-of-three-innovative-oncology-products-in-china-national
https://www.nasdaq.com/press-release/beigene-announces-the-approval-in-china-of-blincytor-blinatumomab-for-injection-for
https://www.nasdaq.com/press-release/beigene-presents-clinical-data-on-brukinsar-zanubrutinib-in-b-cell-malignancies-and
https://www.nasdaq.com/press-release/beigene-announces-data-on-brukinsar-zanubrutinib-from-phase-2-trial-in-marginal-zone
https://www.nasdaq.com/press-release/beigene-announces-pricing-of-public-offering-by-selling-shareholders-2020-12-01
https://www.nasdaq.com/press-release/beigene-launches-proposed-public-offering-by-selling-shareholders-2020-12-01
https://www.nasdaq.com/press-release/beigene-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/beigene-announces-the-approval-of-xgevar-denosumab-in-china-for-the-prevention-of
https://www.nasdaq.com/press-release/beigene-announces-that-rationale-303-trial-of-tislelizumab-in-non-small-cell-lung
https://www.nasdaq.com/press-release/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for
https://www.nasdaq.com/press-release/beigene-reports-third-quarter-2020-financial-results-2020-11-05
https://www.nasdaq.com/press-release/beigene-announces-data-on-brukinsar-zanubrutinib-and-tislelizumab-to-be-presented-at
https://www.nasdaq.com/press-release/bioatla-and-beigene-revise-global-development-and-commercialization-agreement-for
https://www.nasdaq.com/press-release/leap-therapeutics-and-beigene-announce-first-patient-dosed-in-study-of-dkn-01-in
https://www.nasdaq.com/press-release/beigene-presents-data-at-esmo-virtual-congress-2020-on-phase-3-trial-of-tislelizumab
https://www.nasdaq.com/press-release/beigene-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference
https://www.nasdaq.com/press-release/beigene-announces-acceptance-and-priority-review-by-health-canada-of-new-drug
https://www.nasdaq.com/press-release/beigene-announces-inclusion-of-its-shares-in-the-shanghai-hong-kong-and-shenzhen-hong
https://www.nasdaq.com/press-release/beigene-announces-exclusive-license-agreement-for-neutralizing-covid-19-antibodies
https://www.nasdaq.com/press-release/beigene-appoints-corsee-sanders-ph.d.-to-its-board-of-directors-2020-08-25
https://www.nasdaq.com/press-release/bio-thera-solutions-and-beigene-announce-license-distribution-and-supply-agreement
https://www.nasdaq.com/press-release/beigene-reports-second-quarter-2020-financial-results-2020-08-06
https://www.nasdaq.com/press-release/beigene-announces-data-on-tislelizumab-and-pamiparib-to-be-presented-at-the-2020
https://www.nasdaq.com/press-release/priority-review-granted-to-beigenes-new-drug-application-of-pamiparib-in-ovarian
https://www.nasdaq.com/press-release/assembly-biosciences-and-beigene-announce-license-and-collaboration-agreement-in
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-new-drug-application-of-pamiparib-in-ovarian-cancer
https://www.nasdaq.com/press-release/beigene-announces-closing-of-approximately-%242.08-billion-registered-direct-offering
https://www.nasdaq.com/press-release/beigene-announces-pricing-of-approximately-%242.08-billion-registered-direct-offering
https://www.nasdaq.com/press-release/beigene-to-host-investor-conference-call-and-webcast-to-discuss-the-companys-early
https://www.nasdaq.com/press-release/beigene-announces-acceptance-of-a-supplemental-new-drug-application-for-1
https://www.nasdaq.com/press-release/leap-therapeutics-and-beigene-announce-exclusive-option-and-license-agreement-for-dkn
https://www.nasdaq.com/press-release/seattle-genetics-and-beigene-announce-global-license-agreement-for-advanced
https://www.nasdaq.com/press-release/lifshitz-miller-llp-announces-investigation-of-aflac-inc.-beigene-ltd.-meredith
https://www.nasdaq.com/press-release/shareholder-alert%3a-hagens-berman-notifies-investors-in-beigene-ltd.-bgne-of
https://www.nasdaq.com/press-release/ambrx-and-beigene-announce-global-research-and-development-collaboration-develop-next
